Octagam Market Report 2026

Octagam Market Overview

• The Octagam market growth in the historic period has been driven by expansion of plasma collection infrastructure, increasing diagnosis of primary immunodeficiencies • Market expansion is supported by growing prevalence of autoimmune and neurological disorders, increasing use in transplant-related complications • Growth Driver: Growth Of The Market Driven By Increase In Immunodeficiency Disorders • Market Trend: Transforming Care For Rare Autoimmune Disorders • North America was the largest region in 2025.

What Is Covered Under Octagam Market?

Octagam is a brand name for an immune globulin intravenous (IVIG) therapy derived from human plasma. It treats immune deficiencies and certain autoimmune conditions by providing a concentrated dose of antibodies to help strengthen or regulate the immune system. Octagam is administered via intravenous infusion and is typically used under the supervision of medical professionals. The main indication of octagam is primary humoral immunodeficiency, chronic immune thrombocytopenic purpura, dermatomyositis, bone marrow transplantation and AIDs. Primary humoral immunodeficiency is a group of genetic disorders characterized by the absence or dysfunction of antibodies, leading to increased susceptibility to infections. The formulation involved are 5% liquid preparation and 10% liquid preparation which are distributed through pharmacies and online pharmacies.

What Is The Octagam Market Growth Forecast?

The growth in the forecast period can be attributed to growing prevalence of autoimmune and neurological disorders, increasing use in transplant-related complications, expansion of home infusion services, advancements in plasma processing technology, rising investments in immunotherapy research. Major trends in the forecast period include increasing use of ivig in autoimmune disorders, rising demand for plasma-derived therapies, expansion of immunodeficiency treatment applications, enhanced safety through pathogen reduction, growing focus on standardized immunoglobulin products.

Global Octagam Market Segmentation

1) By Indication: Primary Humoral Immunodeficiency, Chronic Immune Thrombocytopenic Purpura, Dermatomyositis, Bone Marrow Transplantation, AIDS 2) By Formulation: 5% Liquid Preparation, 10% Liquid Preparation 3) By Distribution Channel: Pharmacies, Online Pharmacies

What Are The Drivers Of The Octagam Market?

The rise in immunodeficiency disorders is expected to propel the growth of the octagam market going forward. Immunodeficiency disorders are conditions in which the immune system is unable to mount an appropriate response to foreign pathogens or the body’s own tissues, leading to autoimmune diseases or impaired infection-fighting ability. The increase in immunodeficiency disorders is due to factors such as environmental toxins, lifestyle changes, and genetic predispositions, which alter immune responses. Octagam supports patient health by providing immunoglobulin therapy for individuals with primary immunodeficiency diseases, helping prevent infections and manage immune system dysfunction. For instance, in December 2024, according to the U.S. Department of Health & Human Services, a US-based government agency, in 2023, an estimated 39.9 million people worldwide were living with HIV, including 38.6 million adults aged 15 and older and 1.4 million children under 15, with approximately 53% being women and girls. Therefore, the rise in immunodeficiency disorders is driving the growth of the octagam industry. The rise in healthcare expenditure is expected to propel the growth of the octagam going forward. Healthcare expenditure refers to the financial resources spent providing healthcare services, including medical treatments, facilities, personnel, and equipment. Rising healthcare expenditure is driven by factors such as an aging population, increasing prevalence of chronic diseases, advancements in medical technology, and higher patient expectations for quality care. Rising healthcare expenditure increases demand for plasma-derived therapies such as octagam to expand its market and improve patient access to essential treatments. For instance, in April 2025, according to the American Medical Association, a US-based professional organization, U.S. health spending rose 7.5% in 2023 to $4.9 trillion, or $14,570 per person, a marked increase compared with the 4.6% growth recorded in 2022. Therefore, the rise in healthcare expenditure will drive the octagam industry.

Key Players In The Global Octagam Market

Major companies operating in the octagam market are Octapharma AG

Global Octagam Market Trends and Insights

Major companies operating in the Octagam market are focusing on increasing supply resilience, such as high-concentration intravenous immunoglobulin product profile synopsis to enhance clinical clarity and regulatory alignment. High-concentration intravenous immunoglobulin product profile synopsis refers to a structured technical overview describing the key attributes, clinical specifications, and safety-related details of a concentrated intravenous immunoglobulin formulation. For instance, in March 2025, Octapharma, a Switzerland-based plasma products company, launched Gamten 10% IVIg, a 10% human normal immunoglobulin solution manufactured using UK-sourced plasma, which improves self-sufficiency, maintains the same formulation and clinical profile as Octagam 10%, and provides high purity with ≥ 95% IgG and IgA content ≤ 0.4 mg/ml.

Regional Insights

North America was the largest region in the octagam market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Octagam Market?

The octagam market consists of sales of pre-filled syringes, vials, infusion kits, infusion pumps, and tubing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Octagam Market Report 2026?

The octagam market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the octagam industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.